Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Amyloid-beta (Aβ) fibrils and insoluble plaque-associated Aβ represent the aggregated, beta-sheet-rich physical states of the amyloid-beta peptide, which is generated through the sequential proteolytic cleavage of the amyloid precursor protein (APP) by beta- and gamma-secretases. While monomeric Aβ is soluble and may have physiological roles, its misfolding and self-assembly into oligomers, protofibrils, and eventually mature insoluble fibrils lead to the formation of senile plaques in the brain parenchyma. These fibrillar aggregates and plaques are hallmark neuropathological features of Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA). They act as reservoirs of neurotoxicity, inducing synaptic dysfunction, neuroinflammation, oxidative stress, and downstream tau pathology, ultimately leading to neuronal death and cognitive decline.
Therapeutic strategies targeting these insoluble aggregates primarily utilize monoclonal antibodies designed to recognize specific conformational epitopes of aggregated Aβ. Upon binding, these antibodies facilitate the clearance of plaques and fibrils through microglial-mediated phagocytosis. Clinical trials of anti-Aβ antibodies, such as lecanemab and donanemab, have demonstrated that substantial reduction of the amyloid plaque burden can modestly slow cognitive and functional decline in patients with early-stage Alzheimer's disease. However, targeting these insoluble structures is associated with significant safety concerns, most notably amyloid-related imaging abnormalities (ARIA) characterized by vasogenic edema or microhemorrhages, particularly in patients carrying the APOE ε4 allele.
Monoclonal antibodies bind to specific epitopes on amyloid-beta fibrils or plaque-associated aggregates, marking them for clearance via microglial-mediated phagocytosis. Other therapeutic approaches, such as small molecules or peptides, aim to inhibit fibril elongation, prevent aggregation, or promote the disassembly and dissociation of pre-formed fibrils into non-toxic monomeric species.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Amyloid-beta protein fibrils (Aβ fibrils).